Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology and Diagnostic Forum
Get Alerts VRML Hot Sheet
Join SI Premium – FREE
AUSTIN, Texas, Nov. 14, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology and Diagnostics Forum Conference.
Medical Technology & Diagnostics Forum | |
Date: |
Thursday, November 17, 2016 |
Time: |
3:30pm Eastern Time |
Location: |
Westin Grand Central, New York |
About Vermillion Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with debilitating diseases. The company's initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use and which uses widely distributed platforms. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact: Michael WoodLifeSci Advisors LLCTel 1-646-597-6983[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-present-corporate-overview-at-the-canaccord-genuity-medical-technology-and-diagnostic-forum-300359440.html
SOURCE Vermillion, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- In Vitro Fertilization (IVF) Market Booming! and Projected to Reach USD 38.96 Billion by 2031 Driven by Rising Reproductive Tourism and Increasing Infertility Rates
- Jessup House Provides Perfect Backdrop for Philadelphia Life
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!